Literature DB >> 22332994

Recommendations for the implementation of platelet autoantibody testing in clinical trials of immune thrombocytopenia.

D M Arnold1, S Santoso, A Greinacher.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22332994      PMCID： PMC4854629          DOI： 10.1111/j.1538-7836.2012.04664.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  10 in total

1.  Platelet-associated anti-GPIIb-IIIa autoantibodies in chronic immune thrombocytopenic purpura recognizing epitopes close to the ligand-binding site of glycoprotein (GP) IIb.

Authors:  S Kosugi; Y Tomiyama; S Honda; H Kato; T Kiyoi; H Kashiwagi; Y Kurata; Y Matsuzawa
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

2.  A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia.

Authors:  Donald M Arnold; Nancy M Heddle; Julie Carruthers; Deborah J Cook; Mark A Crowther; Ralph M Meyer; Yang Liu; Richard J Cook; Anne McLeod; Janet A MacEachern; Joy Mangel; David Anderson; Linda Vickars; Alan Tinmouth; Andre C Schuh; John G Kelton
Journal:  Blood       Date:  2012-01-05       Impact factor: 22.113

3.  Report on the 14th International Society of Blood Transfusion Platelet Immunology Workshop.

Authors:  G G Wu; C Kaplan; B R Curtis; H A Pearson
Journal:  Vox Sang       Date:  2010-11       Impact factor: 2.144

Review 4.  The ITP syndrome: pathogenic and clinical diversity.

Authors:  Douglas B Cines; James B Bussel; Howard A Liebman; Eline T Luning Prak
Journal:  Blood       Date:  2009-04-24       Impact factor: 22.113

Review 5.  The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia.

Authors:  Cindy Neunert; Wendy Lim; Mark Crowther; Alan Cohen; Lawrence Solberg; Mark A Crowther
Journal:  Blood       Date:  2011-02-16       Impact factor: 22.113

6.  A prospective comparison of four techniques for measuring platelet-associated IgG.

Authors:  J G Kelton; W G Murphy; A Lucarelli; J Garvey-Williams; A Santos; R Meyer; P Powers
Journal:  Br J Haematol       Date:  1989-01       Impact factor: 6.998

7.  A prospective study of protein-specific assays used to investigate idiopathic thrombocytopenic purpura.

Authors:  M N Warner; J C Moore; T E Warkentin; A V Santos; J G Kelton
Journal:  Br J Haematol       Date:  1999-03       Impact factor: 6.998

8.  Autoantibodies to alpha(IIb)beta(3) in patients with chronic immune thrombocytopenic purpura bind primarily to epitopes on alpha(IIb).

Authors:  R McMillan; J Lopez-Dee; J C Loftus
Journal:  Blood       Date:  2001-04-01       Impact factor: 22.113

9.  Prospective evaluation of the clinical usefulness of an antigen-specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias.

Authors:  T A Brighton; S Evans; P A Castaldi; C N Chesterman; B H Chong
Journal:  Blood       Date:  1996-07-01       Impact factor: 22.113

10.  Prospective evaluation of the immunobead assay for the diagnosis of adult chronic immune thrombocytopenic purpura (ITP).

Authors:  R McMillan; L Wang; P Tani
Journal:  J Thromb Haemost       Date:  2003-03       Impact factor: 5.824
  10 in total
  10 in total

1.  Platelet autoantibodies in the bone marrow of patients with immune thrombocytopenia.

Authors:  Sabrina Shrestha; Ishac Nazy; James W Smith; John G Kelton; Donald M Arnold
Journal:  Blood Adv       Date:  2020-07-14

2.  A modern reassessment of glycoprotein-specific direct platelet autoantibody testing in immune thrombocytopenia.

Authors:  Hanny Al-Samkari; Rachel P Rosovsky; Rebecca S Karp Leaf; David B Smith; Katayoon Goodarzi; Annemarie E Fogerty; David B Sykes; David J Kuter
Journal:  Blood Adv       Date:  2020-01-14

Review 3.  Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch.

Authors:  Brian A Baldo; Nghia H Pham
Journal:  Cancer Metastasis Rev       Date:  2013-12       Impact factor: 9.264

Review 4.  Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses.

Authors:  Brian A Baldo
Journal:  Oncoimmunology       Date:  2013-10-17       Impact factor: 8.110

5.  Anti-platelet antibodies in childhood immune thrombocytopenia: Prevalence and prognostic implications.

Authors:  David E Schmidt; Katja M J Heitink-Polle; Leendert Porcelijn; C Ellen van der Schoot; Gestur Vidarsson; Marrie C A Bruin; Masja de Haas
Journal:  J Thromb Haemost       Date:  2020-04-12       Impact factor: 5.824

6.  Detection and dynamics of anti-platelet antibodies in thrombocytopenic dogs with and without idiopathic immune thrombocytopenia.

Authors:  Sarah Shropshire; Steven Dow; Michael Lappin
Journal:  J Vet Intern Med       Date:  2020-02-18       Impact factor: 3.333

7.  Platelet variability index: a measure of platelet count fluctuations in patients with immune thrombocytopenia.

Authors:  Na Li; Nancy M Heddle; Ishac Nazy; John G Kelton; Donald M Arnold
Journal:  Blood Adv       Date:  2021-10-26

8.  Antiplatelet antibody predicts platelet desialylation and apoptosis in immune thrombocytopenia.

Authors:  Shiying Silvia Zheng; Zohra Ahmadi; Halina Hoi Laam Leung; Rose Wong; Feng Yan; Jose Sail Perdomo; Beng Hock Chong
Journal:  Haematologica       Date:  2022-09-01       Impact factor: 11.047

9.  Anti-Human Platelet Antigen-1a Immunoglobulin G Preparation Intended to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia.

Authors:  Ying-Jan Weng; Anne Husebekk; Björn Skogen; Mette Kjaer; Liang-Tzung Lin; Thierry Burnouf
Journal:  PLoS One       Date:  2016-09-14       Impact factor: 3.240

10.  Anti-platelet antibody immunoassays in childhood immune thrombocytopenia: a systematic review.

Authors:  David E Schmidt; Anke J Lakerveld; Katja M J Heitink-Pollé; Marrie C A Bruin; Gestur Vidarsson; Leendert Porcelijn; Masja de Haas
Journal:  Vox Sang       Date:  2020-02-20       Impact factor: 2.144
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.